Epidermal growth factor receptor-targeted peptide conjugated phospholipid micelles for doxorubicin delivery

References

• Schlitt A, Jordan K, Vordermark D, et al. Cardiotoxicity and oncological treatments. Dtsch Arztebl Int 2014;111:161–8
   PubMed Web of Science ®Google Scholar
• Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol 2010;188:759–68
   PubMed Web of Science ®Google Scholar
• Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci 2013;48:416–27
   PubMed Web of Science ®Google Scholar
• Mohri K, Nishikawa M, Takahashi Y, Takakura Y. DNA nanotechnology-based development of delivery systems for bioactive compounds. Eur J Pharm Sci 2014;58:26–33
   PubMed Web of Science ®Google Scholar
• Song S, Liu D, Peng J, et al. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm 2008;363:155–61
   PubMed Web of Science ®Google Scholar
• Tan ML, Choong PF, Dass CR. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides 2010;31:184–93
   PubMed Web of Science ®Google Scholar
• Zhang G, Zeng X, Li P. Nanomaterials in cancer-therapy drug delivery system. J Biomed Nanotechnol 2013;9:741–50
   PubMed Web of Science ®Google Scholar
• Tang N, Du G, Wang N, et al. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst 2007;99:1004–15
   PubMed Web of Science ®Google Scholar
• Kastantin M, Ananthanarayanan B, Karmali P, et al. Effect of the lipid chain melting transition on the stability of DSPE-PEG(2000) micelles. Langmuir 2009;25:7279–86
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang R, Lu X, et al. Pegylated phospholipids-based self-assembly with water-soluble drugs. Pharm Res Dordr 2010;27:361–70
   PubMed Web of Science ®Google Scholar
• Wei T, Liu J, Ma H, et al. Functionalized nanoscale micelles improve drug delivery for cancer therapy in vitro and in vivo. Nano Lett 2013;13:2528–34
   PubMed Web of Science ®Google Scholar
• Xu YH, Richert N, Ito S, et al. Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc Natl Acad Sci USA 1984;81:7308–12
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Bio 2001;2:127–37
   PubMed Web of Science ®Google Scholar
• Nicholson R, Gee J, Harper M. EGFR and cancer prognosis. Eur J Cancer 2001;37:9–15
   PubMed Web of Science ®Google Scholar
• Klutz K, Schaffert D, Willhauck MJ, et al. Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene. Mol Ther 2011;19:676–85
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787–99
   PubMed Web of Science ®Google Scholar
• Julien DC, Behnke S, Wang G, et al. Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer. mAbs 2011;3:467–78
   PubMed Web of Science ®Google Scholar
• Medina OP, Pillarsetty N, Glekas A, et al. Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system. J Control Release 2011;149:292–8
   PubMed Web of Science ®Google Scholar
• Yuan Y, Chen S, Paunesku T, et al. Epidermal growth factor receptor targeted nuclear delivery and high-resolution whole cell X-ray imaging of Fe3O4@TiO2 nanoparticles in cancer cells. ACS Nano 2013;7:10502–17
   PubMed Web of Science ®Google Scholar
• Li Z, Zhao R, Wu X, et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J 2005;19:1978–85
   PubMed Web of Science ®Google Scholar
• Schafer A, Pahnke A, Schaffert D, et al. Disconnecting the yin and yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: a fully synthetic, EGFR-targeted gene transfer system avoiding receptor activation. Hum Gene Ther 2011;22:1463–73
   PubMed Web of Science ®Google Scholar
• Abourbeh G, Shir A, Mishani E, et al. PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors. IUBMB Life 2012;64:324–30
   PubMed Web of Science ®Google Scholar
• Liu M, Li ZH, Xu FJ, et al. An oligopeptide ligand-mediated therapeutic gene nanocomplex for liver cancer-targeted therapy. Biomaterials 2012;33:2240–50
   PubMed Web of Science ®Google Scholar
• Ohno S, Takanashi M, Sudo K, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther 2013;21:185–91
   PubMed Web of Science ®Google Scholar
• Kopansky E, Shamay Y, David A. Peptide-directed HPMA copolymer-doxorubicin conjugates as targeted therapeutics for colorectal cancer. J Drug Target 2011;19:933–43
   PubMed Web of Science ®Google Scholar
• Liu CW, Lin WJ. Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells. J Drug Target 2013;21:776–86
   PubMed Web of Science ®Google Scholar
• Stefanick JF, Ashley JD, Bilgicer B. Enhanced cellular uptake of peptide-targeted nanoparticles through increased peptide hydrophilicity and optimized ethylene glycol peptide-linker length. ACS Nano 2013;7:8115–27
   PubMed Web of Science ®Google Scholar
• Lee TY, Wu HC, Tseng YL, Lin CT. A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res 2004;64:8002–8
   PubMed Web of Science ®Google Scholar
• Nam HY, Kwon SM, Chung H, et al. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J Control Release 2009;135:259–67
   PubMed Web of Science ®Google Scholar
• Jiang H, Wang H, Tan Z, et al. Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III. J Biol Chem 2011;286:5913–20
   PubMed Web of Science ®Google Scholar
• Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release 2008;126:187–204
   PubMed Web of Science ®Google Scholar
• Shenoy D, Little S, Langer R, Amiji M. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. 1. In vitro evaluations. Mol Pharmaceut 2005;2:357–66
   PubMed Web of Science ®Google Scholar
• Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991;88:11460–4
   PubMed Web of Science ®Google Scholar
• Torchilin VP. PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv Drug Deliver Rev 2002;54:235–52
   PubMed Web of Science ®Google Scholar